Definium Therapeutics (DFTX)
Develops lysergide and R(-)-MDMA drug candidates for anxiety, depression and autism.
$40.00
After hours−0.33 (−0.82%)
At close$40.33(+2.67%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 83.90% | 112.74M shares | |
|---|---|---|---|
| 388 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.41% | 4.58M shares | |
| 12 holders · as of Sep 18, 2026 | |||
| Other | ≈ 12.69% | 17.05M shares | |
| remainder | |||
134.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
388 holders · 112.74M shares · 154 new positions · 271 increased · 66 reduced · 35 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 11.23M | 8.36% | +2.75M | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 7.19M | 5.35% | +2.19M | Aug 14, 2026 |
| Driehaus Capital Management LLC | 6.85M | 5.09% | +933.4K | Aug 14, 2026 |
| Jupiter Topco LLC | 5.62M | 4.18% | +5.62Mnew | Aug 14, 2026 |
| Capital World Investors | 5.37M | 3.99% | +5.37Mnew | Aug 12, 2026 |
| FMR LLC | 4.75M | 3.54% | +2.94M | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 4.65M | 3.46% | +4.58M | Aug 14, 2026 |
| Geode Capital Management, LLC | 3.64M | 2.71% | +1.15M | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.30% | 6.07M | 13G | Feb 5, 2025 |
| Commodore Capital LP | 7.20% | 7.43M | 13G | Feb 17, 2026 |
| Deep Track Capital, LP | 6.87% | 5.50M | 13G | Nov 14, 2025 |
| Driehaus Capital Management LLC | 6.64% | 6.54M | 13G | Feb 17, 2026 |
| Avoro Capital Advisors LLC | 5.08% | 5.00M | 13G | Feb 17, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 3, 2026 | Robert Barrowdirector, officer: Chief Executive Officer | Sale | 19,023 | $37.94 | 1,494,640 |
| Jun 25, 2026 | Matthew T. Wileyofficer: Chief Commercial Officer | Sale | 2,867 | $45.03 | 174,633 |
| Jun 25, 2026 | Daniel Karlinofficer: Chief Medical Officer | Sale | 10,035 | $45.03 | 503,282 |
| Jun 25, 2026 | Robert Barrowdirector, officer: Chief Executive Officer | Sale | 29,208 | $45.03 | 1,098,246 |
| Jun 25, 2026 | Brandi Robertsofficer: Chief Financial Officer | Sale | 3,013 | $45.03 | 209,487 |
| Jun 25, 2026 | Mark Sullivanofficer: Chief Legal Officer | Sale | 13,008 | $45.03 | 320,571 |
| Mar 25, 2026 | Robert Barrowdirector, officer: Chief Executive Officer | Sale | 24,431 | $18.47 | 752,454 |
| Mar 25, 2026 | Mark Sullivanofficer: Chief Legal Officer | Sale | 10,702 | $18.47 | 271,079 |
| Mar 25, 2026 | Daniel Karlinofficer: Chief Medical Officer | Sale | 8,018 | $18.47 | 413,317 |
| Dec 26, 2025 | Mark Sullivanofficer: Chief Legal Officer | Sale | 11,276 | $13.15 | 282,576 |
House and Senate disclosures
Not reported.